The disclosure relates to a method for estimating the effectiveness of treatment with a T-lymphocyte cell co-stimulation modulator agent in a patient with rheumatoid arthritis and who has had an inadequate response to prior biotherapy, consisting in analysing a biological sample of said patient for the expression of a set of biomarkers, the results of which make it possible to determine whether said modulator agent is a treatment that will engender a beneficial response for said patient. The disclosure also relates to a system for estimating the effectiveness of said treatment in said patient comprising means for measuring or receiving data concerning the expression level of said biomarkers and means for processing these data configured to estimate said effectiveness of said treatment in said patient. The biomarkers comprise at least two biomarkers selected from the group consisting of C4b-Binding Protein, C-Reactive Protein, Cartilage Oligomeric Matrix Protein, Fibronectin and Lipopolysaccharide-Binding Protein.
METHOD FOR ESTIMATING THE EFFECTIVENESS AGAINST RHEUMATOID ARTHRITIS OF A T-LYMPHOCYTE CO-STIMULATION MODULATOR AGENT